Please ensure Javascript is enabled for purposes of website accessibility

5 of Last Week's Biggest Winners

By Rick Munarriz - Updated Apr 6, 2017 at 10:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These five stocks made longs a lot of money last week.

What's better than momentum? Mo' momentum.

Let's take a closer look at five of this past week's biggest scorchers.

Company

Apr. 15

Weekly Gain

My Watchlist

Global Crossing (Nasdaq: GLBC)

$25.78

74%

Add

Idenix (Nasdaq: IDIX)

$4.24

46%

Add

Sify (Nasdaq: SIFY)

$5.81

38%

Add

Graham Packaging (NYSE: GRM)

$22.98

37%

Add

Acorda Therapeutics (Nasdaq: ACOR)

$29.15

32%

Add

Source: Barron's.

Global Crossing was the market's hottest stock, soaring 74% after agreeing to be acquired by Level 3 (Nasdaq: LVLT). The all-stock deal was originally for a 56% premium, but Global Crossing's stock surpassed the $1.9 billion takeover bid as Level 3's shares also took off on the news.

Idenix Pharmaceuticals bounced back from an unpopular secondary offering earlier this month when Novartis (NYSE: NVS) revealed that it was tacking on to its already sizable position. This doesn't mean that the Swiss drug giant is out to acquire all of Idenix, but buying in after the secondary is a welcome act of validation.

Sify continued to add to the monster gains it has amassed in recent weeks. The Indian provider of connectivity, hosting, and other IT-related services is seen as a great play on the colossal upside of India's online migration. The shares have nearly doubled since I recommended it as a portfolio replacement three months ago.

The biggest winner on the New York Stock Exchange was Graham Packaging. The plastic container maker is being acquired by rival Silgan Holdings in a $4.1 billion deal.

Shares of Acorda were halted -- and then kept climbing -- after an analyst report speculated that its multiple sclerosis drug may be receiving a patent extension. Acorda's Ampyra improves the walking ability of people with MS.

It was a great week for these five stocks. Now let's see if they're up for an encore.

Which of these five stocks do you think will continue to move higher? Share your thoughts in the comment box below.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acorda Therapeutics, Inc. Stock Quote
Acorda Therapeutics, Inc.
ACOR
$0.48 (3.20%) $0.01
Sify Technologies Limited Stock Quote
Sify Technologies Limited
SIFY
$1.91 (-2.05%) $0.04
Novartis AG Stock Quote
Novartis AG
NVS
$84.36 (-0.20%) $0.17
Level 3 Communications, Inc. Stock Quote
Level 3 Communications, Inc.
LVLT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.